Table 1

Studies included in the analysis

Inclusion criteria
Study[Ref.]Duration (Age)Symptoms/rescue medicationFEV1/PEFPrevious treatment (dose μg)Comparator treatment (n)
A1 9 During 2-week run-in; ≤3 nights needing rescue medication, ≤3 days with ≥12a puffs rescue medicationFEV1 40–85% predSALM (100) BDP (300–500) TCA (600–1000) FLU (1000) FP (200) BDPSFC 50/100 μg bd (92) SALM 50 μg bd (92) FP 100 μg bd (90) PL (82)
A2 10 12 weeks (≥12 yrs)FEV1 40–85% predBDP (550–800) TCA (1100–1600) FLU (1250–2000) FP (500)SFC 50/250 μg bd (84) SALM 50 μg bd (88) FP 250 μg bd (84) PL (93)
B1 11 12 weeks (≥12 yrs)During week before randomization: ≥3 days with day + night symptom score ≥2PEF 50–85% of post salbutamol valueBDP/BUD (400–500) FP (200–250)SFC 50/100 μg bd (21) SALM 50 μg bd + FP 100 μg bd (concurrently) + (123)
B2 12 12 weeks (≥12 yrs)PEF 50–85% of post salbutamol valueBDP/BUD (800–1200) FP (400–600)SFC 50/250 μg bd (180) SALM 50 μg bd + FP 250 μg bd (concurrently) + (191)
B3 13 28 weeks (≥12 yrs)PEF 50–85% of post salbutamol valueBDP/BUD (1500–2000) FP (750–1000)SFC 50/500 μg bd (167) SALM 50 μg bd + FP 500 μg bd (concurrently) + (171) FP 500 μg bd (165)
B4 14 12 weeks (4–11 yrs)During week before randomization: ≥4 days with day + night symptom scorePEF 50–85% of post salbutamol valueBDP/BUD (400–500) FP (200–250)SFC 50/100 μg bd (125) SALM 50 μg bd + FP 100 μg bd (concurrently) + (132)
C1 15 12 weeks (≥12 yrs)During week before randomization: ≥4 days with day + night symptom score ≥2FEV1 65–85% predBDP/BUD (≤500)SFC 50/100 μg bd (176)
C2 16 24 weeks (≥12 yrs)FEV1 50–85% predBDP/BUD (800–1200)SFC 50/250 μg bd (180) BUD 800 μg bd (173)
  • FEV1: forced expiratory volume in one second; PEF: peak expiratory flow; bd: twice daily; BDP: beclomethasone dipropionate; BUD: budesonide; FLU: flunisolide; FP: fluticasone propionate; PL: placebo; SALM: salmeterol; SFC: salmeterol/fluticasone propionate combination; TCA: triamcinolone acetonide; a: for patients previously on inhaled corticosteroids.